Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, random ised controlled trial.

The article presents a study which examines the effect of adjuvant chemotherapy with capecitabine plus oxaliplatin in the disease-free survival following D2 gastrectomy. The study randomly subjected stage II-IIIB gastric cancer patients, who undergone curative D2 gastrectomy, to adjuvant chemotherapy with oral capecitabine and intravenous oxaliplatin treatment or surgery only. Result shows that chemotherapy patients have 74% of 3 year disease-free survival, while surgery only patients show 59%.